Click Here to return To Results

 

EMA401, An Orally Administered Highly Selective Angiotensin II Type 2 Receptor Antagonist, as a Novel Treatment for Postherpetic Neuralgia: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Lancet 383:1637-1647, Rice, A.C.,et al, 2014 See this aricle in Pubmed Article Abstract EMA401 (100mg twice daily) provides superior relief of postherpetic neuralgia compared with placebo at the end of 28 days of treatment. EMA401 was well tolerated by patients.

Related Tags

(click to filter results - removes previous filter) angiotensin II receptor blocker efficacy neuralgia,treatment of pain pain,neuropathic post herpetic neuralgia safety treatment of neurologic disorder

Click Here to return To Results